Trial reportBritish journal of clinical pharmacology2010
Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.
Trial report in British journal of clinical pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Pharmacokinetic Drug Interaction Studies with Enzalutamide.Clinical pharmacokinetics · 2015Trial
- Clotrimazole as a new frontier: Drug repurposing and its efficacy in cancer therapy.Cancer pathogenesis and therapy · 2026Review
- EBI2-oxysterol signalling regulates VE-cadherin expression and multiple sclerosis CD4Brain, behavior, & immunity - health · 2025Article
- Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection.Clinical pharmacology and therapeutics · 2022Article
- Evaluation of clotrimazole prophylaxis on tacrolimus trough concentrations in kidney transplant recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2022Article
- Application of target repositioning and in silico screening to exploit fatty acid binding proteins (FABPs) from Echinococcus multilocularis as possible drug targets.Journal of computer-aided molecular design · 2020Article
- Drug interactions between tacrolimus and clotrimazole troche: a data mining approach followed by a pharmacokinetic study.European journal of clinical pharmacology · 2020Article
- Clotrimazole troches can alter everolimus pharmacokinetics in post-transplant patients: A case report.British journal of clinical pharmacology · 2019Article
- Effects of clotrimazole on tacrolimus pharmacokinetics in patients with heart transplants with different CYP3A5 genotypes.European journal of clinical pharmacology · 2019Article
- Author's Reply to Reith: "Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults".Clinical pharmacokinetics · 2018Article
- Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults.Clinical pharmacokinetics · 2018Article
- Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?British journal of clinical pharmacology · 2017Article
- Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach.Drug metabolism and disposition: the biological fate of chemicals · 2017Article
- The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery.Pharmaceutical research · 2015Observational
- Electrophysiological Studies into the Safety of the Anti-diarrheal Drug Clotrimazole during Oral Rehydration Therapy.PLoS neglected tropical diseases · 2015Article
- Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme.Molecules (Basel, Switzerland) · 2012Article
- Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients.Transplantation · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
aimsThe aim of the study was to determine the effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam in the plasma.
methodsWe conducted a randomized, open-label, four-way crossover study in 10 healthy volunteers. Each volunteer received oral midazolam 2 mg or intravenous midazolam 0.025 mg kg(-1) with and without oral clotrimazole troches 10 mg taken three times daily for 5 days. Each study period was separated by 14 days. Serial blood samples were collected up to 24 h after oral midazolam and 6 h after intravenous midazolam. Plasma concentrations for midazolam and its metabolite 1-hydroxymidazolam were measured and fitted to a noncompartmental model to estimate the pharmacokinetic parameters.
resultsTen healthy volunteers aged 21-26 years provided written informed consent and were enrolled into the study. Clotrimazole decreased the apparent oral clearance of midazolam from 57 +/- 13 l h(-1)[95% confidence interval 48, 66] to 36 +/- 9.8 l h(-1) (95% confidence interval 29, 43) (P= 0.003). These changes were accompanied by a decrease in the area under the concentration-time curve (mean difference 22 microg h(-1) l(-1), P= 0.001) and bioavailability (mean difference 0.21, P= NS). There were no significant differences in the systemic clearance of midazolam with or without clotrimazole troches.
conclusionsOral clotrimazole troches decreased the apparent oral clearance of midazolam; no significant differences in the systemic clearance of midazolam were found.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.